A Double-Blind, Placebo-Controlled, Crossover Study Examining the Acute Effects of Olanzapine on Plasma Leptin, Glucose Tolerance and Free Fatty Acids in Healthy Volunteers.
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2011
At a glance
- Drugs Olanzapine (Primary)
- Indications Bipolar disorders; Schizophrenia
- Focus Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 21 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.